Investigating how lymphoma cells resist treatment with PRMT5 inhibitors
Official title: Understanding resistance mechanisms to protein arginine methyltransransferase Inhibitors in Lymphoma
Funded at Sloan-Kettering Inst Can Research · NIH-11013353 · Data updated 2026-11-12
This study is looking into why some people with Non-Hodgkin's lymphoma don't get better with treatments that target a specific enzyme, and it aims to find out how a protein called MUSASHI2 affects this, which could help develop better treatments for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | March 13, 2023 |
| Project end | February 29, 2028 |
| Funding year | 2025 |
| Award (this year) | $694,643 |
| NIH project number | 5R01CA274249-03 |
| Project ID | NIH-11013353 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include adults diagnosed with Non-Hodgkin's lymphoma who have experienced treatment resistance.
✕Less likely to help
Patients with other types of cancer or those who have not been diagnosed with Non-Hodgkin's lymphoma may not benefit from this research.
What this research studies
This research focuses on understanding why some patients with Non-Hodgkin's lymphoma do not respond to treatments targeting a specific enzyme called PRMT5. The team uses advanced techniques, including CRISPR screening, to identify genetic factors that contribute to treatment resistance. By studying both mouse models and human lymphoma cell lines, they aim to uncover the role of a protein called MUSASHI2 in lymphoma progression and treatment response. This could lead to new strategies for overcoming resistance and improving patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with Non-Hodgkin's lymphoma, particularly those who currently experience relapses.
How similar studies have gone: Other research has shown promising results in targeting PRMT5 in various cancers, suggesting that this approach may be effective in lymphoma as well.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Kharas, Michael — Sloan-Kettering Inst Can Research
- Study coordinator: Kharas, Michael
Related research
Other NIH-funded projects on the same topics.
-
Understanding why Black and Hispanic Hodgkin lymphoma patients have worse survival
A patient-centered study to uncover social and care factors that contribute to lower survival among Black and Hispanic people with Hodgkin lymphoma across all ages.
-
Preventing follicular lymphoma progression with precision therapy
This grant tests a targeted approach to stop follicular lymphoma from getting worse or turning into a more aggressive cancer.
-
Novel combination therapy for non-Hodgkin lymphoma in people and dogs
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
-
Cyclin D1 and DNA Repair in Mantle Cell Lymphoma: A Path to New Therapies
A clinician-researcher at Mayo Clinic is pursuing advanced training and research to understand how Cyclin D1 drives replication stress and to explore new targeted treatments for high-risk mantle cell lymphoma.
-
Targeting the IL-1R Pathway to Boost Immunotherapy for Anaplastic Large Cell Lymphoma
Aims to make CD30 CAR therapies work better for people with ALCL by blocking a immune-evasion pathway.
-
Radiation Therapy Innovation to Improve Lymphoma Trials and Carbon Ion Research Path
A Mayo Clinic-led effort to better design and run lymphoma trials by integrating advanced radiation therapy and exploring carbon ion radiotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.